Shots:
- Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno, expanding its endocrinology & rare disease portfolio
- As per the deal, Neurocrine will acquire Soleno for $53/share in cash, representing a total transaction equity value of $2.9B
- Acquisition will add Vykat XR (diazoxide choline) to Neurocrine’s portfolio for the treatment of hyperphagia with Prader-Willi syndrome, which is supported by a strong IP that is expected to extend into the mid-2040s
Ref: PRnewswire | Image: Soleno | Press Release
Related News: Neurocrine Biosciences Initiates P-II Study of NBI-1065890 to Treat Tardive Dyskinesia (TD) in Adults
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
